论文部分内容阅读
目的观察蚓激酶治疗老年冠心病的临床疗效和不良反应。方法选择120例老年冠心病患者,随机分为治疗组和观察组,治疗组60例,在常规治疗的基础上加用蚓激酶治疗,另60例(对照组)常规治疗。观察治疗前后血尿常规、血糖、血脂、肝肾功能、心电图、血压及药物不良反应。结果治疗组心绞痛改善总有效率90%(显效率62%,有效率28%);对照组总有效率70%(显效率22%,有效率48%);治疗组心电图恢复总有效率70%(显效率42%,有效率28%);对照组总有效率44%(显效率30%,有效率14%)。两组疗效差异有统计学意义(P<0.05)。治疗前后肝肾功能、血尿常规均无明显变化。结论蚓激酶治疗老年冠心病有明显临床疗效,安全性高,不良反应轻微。
Objective To observe the clinical efficacy and adverse reactions of lumbrokinase in elderly patients with coronary heart disease. Methods A total of 120 elderly patients with coronary heart disease were selected and randomly divided into treatment group and observation group. 60 patients in the treatment group were treated with lumbrokinase on the basis of conventional therapy and 60 patients in the control group were routinely treated. Before and after treatment, hematuria, blood glucose, blood lipid, liver and kidney function, electrocardiogram, blood pressure and adverse drug reactions were observed. Results The total effective rate of angina improved 90% (effective rate 62%, effective rate 28%) in the treatment group; the total effective rate 70% (effective rate 22%, effective rate 48%) in the control group; the total effective rate of electrocardiogram recovery was 70% (Markedly effective 42%, effective 28%); control group, the total effective rate 44% (markedly effective rate 30%, effective rate 14%). The difference between the two groups was statistically significant (P <0.05). Liver and kidney function before and after treatment, hematuria routine no significant change. Conclusion Lumbrokinase has obvious clinical efficacy in elderly patients with coronary heart disease, with high safety and mild adverse reactions.